Arcoma AB

Arcoma maintains a strong liquidity position with a current ratio of 3.49 and no long-term debt, indicating a conservative capital structure. The company's liquidity risk is assessed as low, supported by positive operating and free cash flows of 18.72 million SEK and 6.75 million SEK, respectively. Profitability metrics show a return on equity of 6.73% and a return on assets of 5.2%, which are in line with the industry's median performance for advanced medical equipment firms. The company's operating margin of 4.8% and net margin of 3.8% reflect a typical margin profile for firms in this capital-light, high-margin industry. Arcoma's revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company operates primarily in the Nordic region, which represents a relatively small and stable market for medical equipment. This lack of geographic diversification may limit growth potential in the long term. The company's revenue growth outlook for the current fiscal year is modest, with analysts forecasting a 3.2% increase to 135 million SEK. This aligns with the company's historical growth trajectory, which has been relatively flat over the past three years. No significant capital expenditures are expected in the near term, as the company's capex has been negative in recent periods. Arcoma's risk profile is characterized by low liquidity and dilution risk. The company has no immediate filing-based liquidity or dilution flags, and its capital structure remains debt-free. The absence of long-term debt and the presence of positive free cash flow reduce the likelihood of near-term dilution. No recent equity issuance or ATM programs have been disclosed. Recent filings and transcripts indicate that Arcoma is focused on expanding its product portfolio and strengthening its position in the Nordic market. The company has not disclosed any material regulatory or litigation risks in its latest filings.